U.S. FDA Fast-tracks Nektar Therapeutics’ Rezpegaldesleukin for Severe-to-Very-Severe AA July 29, 2025
Raising the Bar in Atopic Dermatitis: Unpacking the practice-changing implications of the LEVEL UP study in AD